Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Breast Cancer Toxicity (CANTO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01993498
Recruitment Status : Recruiting
First Posted : November 25, 2013
Last Update Posted : April 5, 2022
Sponsor:
Information provided by (Responsible Party):
UNICANCER

Brief Summary:

The aims of the cohort will be to quantify impact of cancer treatments toxicities , and to generate predictors of chronic toxicity in patients with non-metastatic breast cancer.

The project will include four specific aims :

  1. To develop a database of chronic treatment related toxicity in a cohort of 14750 women with stage I-III breast cancer (= non metastatic), whatever these treatments are (surgery; radiation therapy; chemotherapy …)
  2. To describe incidence, clinical presentation, and outcome of chronic toxicities over a maximum of 8 years.
  3. To describe the psychological, the social and the economic impacts of chronic toxicities.
  4. To generate predictors for chronic toxicities in order to prevent them, based upon biological criteria.

The expected impact of these toxicities, when identified, will be to improve quality of life and to decrease health cost, by the early identification of patients at high risk of toxicity. Such early identification could lead to prevent toxic effect by: a. developing prevention strategies, b. substituting toxic treatment by a non (less) toxic one.

Also, such cohort will offer a quantification of the impact of treatment toxicity, that could be further used to quantify medical usefulness of strategies that aim at decreasing treatment toxicities (implementation of predictive biomarker for resistance, cytotoxic-free regimen etc…)


Condition or disease Intervention/treatment Phase
Breast Cancer Nos Metastatic Recurrent Procedure: blood sampling Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 14750 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Breast Cancer
Actual Study Start Date : February 20, 2012
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : March 2034

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
breast cancer treatment + blood sampling
Standard treatment of breast cancer with intervention : samples collection
Procedure: blood sampling
blood samples collection




Primary Outcome Measures :
  1. Evaluation of chronic toxicity in patients treated for non-metastatic breast cancer [ Time Frame: 8 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Patient with disease ( 14550)

Inclusion Criteria:

  • Women,
  • Aged 18 years and over,
  • With an invasive breast cancer diagnosed by cytology or histology,
  • Tumors cT0 to cT3, CN0-3,
  • No clinical evidence of metastasis at the time of inclusion,
  • Untreated including scored for breast cancer surgery in progress,
  • Patient receiving a social security system,
  • Patient mastering the French language,
  • Free and informed consent for additional biological samples, different questionnaires and collecting information on resource usage.
  • (Since february 2022) Patient :

    1. Age < 45 years at diagnostic
    2. Or CT2-3, cN0-3, HER2+(RH+or RH-) or RH-HER2-

Exclusion Criteria:

  • Metastatic breast cancer,
  • Local recurrence of breast cancer,
  • History of cancer within 5 years prior to entry into the trial other than basal cell skin or carcinoma in situ of the cervix,
  • Already received treatment for breast cancer ongoing,
  • Blood transfusion performed for less than six months,
  • Persons deprived of liberty or under supervision (including guardianship).

Healthy volunteers ( 200)


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01993498


Contacts
Layout table for location contacts
Contact: Sibille Everhard (0)1 44 23 55 51 ext + 33 s-everhard@unicancer.fr
Contact: Anne Laure Martin (0)1 44 23 55 56 al-martin@unicancer.fr

Locations
Layout table for location information
France
Gustave roussy Recruiting
Villejuif, France, 94805
Contact: Fabrice ANDRE    (0)1 42 11 43 71 ext +33      
Principal Investigator: Laetitia Shanna RAJPAR         
Principal Investigator: Patrick SOULIE         
Principal Investigator: Severine GUIU         
Principal Investigator: Laurence VANLEMMENS         
Principal Investigator: Marion FOURNIER         
Principal Investigator: Anne LESUR         
Principal Investigator: Olivier TREDAN         
Principal Investigator: Paul henri COTTU         
Principal Investigator: Christelle LEVY         
Principal Investigator: Mario CAMPONE         
Principal Investigator: Carole TARPIN         
Principal Investigator: Florence LEREBOURS         
Principal Investigator: Hervé CURE         
Principal Investigator: Marie Ange MOURET REYNIER         
Principal Investigator: Olivier RIGAL         
Principal Investigator: Jean Marc FERRERO         
Principal Investigator: Thierry PETIT         
Principal Investigator: Pierre KERBRAT         
Principal Investigator: Antoine ARNAUD         
Sponsors and Collaborators
UNICANCER
Investigators
Layout table for investigator information
Principal Investigator: Fabrice André Gustave Roussy - Villejuif
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: UNICANCER
ClinicalTrials.gov Identifier: NCT01993498    
Other Study ID Numbers: UC-0140/1103 CANTO
2011-A01095-36 ( Other Identifier: French Conpetant Authority )
First Posted: November 25, 2013    Key Record Dates
Last Update Posted: April 5, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Unicancer will share de-identified individual data that underlie the results reported. A decision concerning the sharing of other study documents, including protocol and statistical analysis plan will be examined upon request.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: The data shared will be limit to that required for independent mandated verification of the published results, the applicant will need authorization from Unicancer for personal access, and data will only be transferred after signing of a data access agreement.
Access Criteria: Unicancer will consider access to study data upon written detailed request sent to Unicancer, from 6 months until 5 years after publication of summary data.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by UNICANCER:
cancer toxicities
cohort
breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases